## This week in therapeutics

| Indication | Target/marker/pathway | Summary | Licensing status | Publication and contact information |
|---|---|---|---|---|
| **Cancer** | | | | |
| Lung cancer | SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily a member 4 (SMARCA4; BRG1) | Cell culture studies suggest inhibiting BRG1 could help treat *MYC associated factor X* (*MAX*) mutant small cell lung cancer (SCLC). Sequencing of a panel of SCLC cell lines and primary tumors identified tumor-specific, homozygous, *MAX*-inactivating mutations in about 6% of cases. In *MAX*-mutant SCLC cells, shRNA against BRG1 decreased cell growth compared with scrambled control. Next steps could include developing and testing inhibitors of BRG1 in *MAX*-inactivated cancers.<br><br>*SciBX* 7(7); doi:10.1038/scibx.2014.198<br>Published online Feb. 20, 2014 | Patent and licensing status unavailable | Romero, O.A. *et al. Cancer Discov.*; published online Dec. 20, 2013; doi:10.1158/2159-8290.CD-13-0799<br>**Contact:** Montse Sanchez-Cespedes, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain<br>e-mail: mscespedes@idibell.cat |